Uterine scraping as first treatment for low-risk GTN
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether using a hysteroscope (a tiny camera) to gently scrape the uterus again, instead of starting chemotherapy right away, can effectively treat a low-risk, pregnancy-related tumor that returns after a molar pregnancy. It's for Chinese women whose disease is still in an early, low-risk stage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman 60 years or younger from China.
- You have a low-risk type of GTN (a pregnancy-related tumor) that returns after a molar pregnancy.
- Your WHO risk score must be 4 or lower (a measure of how active the disease is).
- You haven't received any treatment for this condition yet.
- Your general health is good – you are up and about, and your blood counts and liver/kidney function are within safe ranges.
- You do not have a certain rare subtype (PSTT or ETT) and lung spots are small (under 2 cm) and few (less than 5).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different treatment approaches for hydatidiform mole when a CT scan shows lung nodules and the team cannot rule out spread. It may help guide the safest next steps and follow-up plan.
This trial tests a combination of an immunotherapy drug (toripalimab) and a chemotherapy drug (actinomycin-D) as the first treatment for gestational trophoblastic neoplasia (GTN) with a FIGO score of 5-6. It may help patients whose disease is at a moderate risk level.
This trial is creating a database for women diagnosed with gestational trophoblastic neoplasia (GTN), which includes tumors that can develop after a molar pregnancy or other pregnancy-related conditions. By joining, you help researchers better understand and improve treatment for these rare tumors.
This trial tests a combination of two drugs — toripalimab (an immunotherapy) and actinomycin-D (chemotherapy) — as the first treatment for a specific type of pregnancy-related tumor (GTN) with a FIGO score of 7. The goal is to see if this combination works better than standard treatment.
This study looks at giving pembrolizumab (a type of immune treatment) before a second evacuation procedure in people with persistent or returning molar pregnancy cancer. The goal is to see if this approach is safe and feasible, and whether it may help control the disease.
This Phase 2 trial studies whether combining camrelizumab (an immune medicine) with apatinib (a medicine that blocks blood-vessel growth) can improve treatment for women with high-risk gestational trophoblastic neoplasia (GTN) that is very high-risk, or has returned or resisted chemotherapy. It may help shrink the tumor and reduce the chance it comes back by using two different approaches together.
Hear when a new Gestational Trophoblastic Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.